Biologics as add-on therapy for treating chronic rhinosinusitis with nasal polyps

Published on 01 Jul 2026
Last Updated on 01 Jul 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended dupilumab, mepolizumab or omalizumab reference biologic (Xolair) for inclusion on the MOH List of Subsidised Drugs for treating chronic rhinosinusitis with nasal polyps, as they were unlikely to represent a cost-effective use of healthcare resources. 

Biologics as add-on therapy for treating chronic rhinosinusitis with nasal polyps (Published 1 July 2026) [PDF, 168.74 KB] ↗ (opens in new tab)

Plain English Summary

Chronic rhinosinusitis is a long-term (chronic) condition where the lining of the nose and sinuses (air-filled spaces in the bones of the face) becomes swollen and inflamed. Over time, this can cause soft, painless, non-cancerous growths (nasal polyps) inside the nose and nasal passages. These polyps can block airflow and cause symptoms such as a blocked or runny nose, lost sense of smell, and pain or pressure in the face.

Dupilumab, mepolizumab and omalizumab are biologic medicines known as monoclonal antibodies. They work by targeting specific parts of the immune system to help reduce the size of nasal polyps and improve symptoms. They are given as an injection under the skin (subcutaneously).

Dupilumab, mepolizumab and omalizumab reference biologic (Xolair) were not recommended for government subsidy because they were considered unlikely to represent a cost-effective use of healthcare resources.

There are different treatments available for chronic rhinosinusitis with nasal polyps. Your doctor can advise whether dupilumab, mepolizumab, omalizumab, or other treatments may be suitable for you.